We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Elicera Therapeutics announced today that the Company's issue of units of approximately SEK 52 million prior to the planned listing on the Nasdaq First North Growth Market was subscribed for approximately 171 percent spread over about 3 600 subscribers.